Aging has quietly become one of the most consequential variables in healthcare, economics, and long-term investing, even though it’s rarely treated that way in capital markets. That gap between impact and attention is where this conversation begins.

My guest is Will Harborne, co-founder and general partner of LongGame Ventures. Will comes to longevity from an unconventional background. He trained as an engineer, spent years in crypto and venture-backed infrastructure, including time at Tether, and built companies in spaces most people still consider speculative. That early exposure to frontier technology shaped how he thinks about risk, incentives, and long time horizons.

We talk about how a personal interest in health and performance gradually pulled him into longevity science, and why he believes aging should be approached as a biological process that can be influenced, not just endured. Will explains how LongGame looks for foundational tools and platforms that address the underlying drivers of aging rather than surface-level wellness trends or short-term fixes.

The conversation also gets practical. We discuss regulatory realities, why longevity companies often have to pursue traditional disease pathways first, and how LongGame constructs a portfolio across multiple scientific approaches instead of betting on a single theory. Throughout, Will is candid about capital discipline, founder judgment, and what it actually takes to build credible companies in a space where timelines are long and certainty is rare.

Episode Highlights: 

• [03:45] Will Harborne explains his early path through engineering and crypto infrastructure and how frontier systems thinking shaped his investment mindset.
• [06:10] Lessons from crypto cycles that still apply to longevity investing, including hype management, timing risk, and incentive design.
• [08:20] The transition from personal health optimization to a deeper conviction that aging is a modifiable biological process.
• [10:55] Why longevity attracts strong narratives but requires unusually high scientific and operational discipline.
• [12:40] How longevity companies are mispriced by traditional biotech frameworks and why that creates both risk and opportunity.
• [15:05] Distinguishing credible longevity science from consumer-facing products dressed up as biotech.
• [17:15] How LongGame Ventures defines its thesis around root causes of aging instead of single-indication or trend-driven bets.
• [19:50] The importance of platforms and enabling technologies that accelerate discovery across multiple disease areas.
• [22:30] Regulatory realities of operating in a world where aging is not classified as a disease and how companies navigate that constraint.
• [25:40] Using traditional disease indications as stepping stones toward broader aging-related applications.
• [28:10] Portfolio construction across multiple hallmarks of aging to reduce scientific concentration risk.
• [31:25] Why LongGame avoids anchoring to any single theory of aging, even when data looks compelling early on.
• [33:55] Skepticism toward overhyped longevity narratives and the case for underfunded “picks-and-shovels” infrastructure plays.
• [36:40] Capital efficiency challenges unique to longevity companies compared to traditional early-stage biotech.
• [39:20] How long development timelines change fund strategy, follow-on decisions, and risk tolerance.
• [41:55] What breaks down most often between strong science and viable company-building.
• [44:10] What Will looks for in founders operating at the intersection of science, regulation, and capital markets.
• [46:50] Founder judgment, adaptability, and credibility as survival traits in long-duration ventures.
• [49:35] Ethical considerations around access, safety, and scalability as longevity interventions mature.
• [52:10] Why societal impact and commercial success don’t have to be at odds in longevity investing.
• [55:00] Signs that the longevity sector may be approaching an inflection point and what still needs to align.
• [58:20] Final reflections on patience, realism, and long-term thinking in frontier investing.

Resources & Links Related to this Episode

• LongGame Ventures - Will Harborne
• LongGame Ventures
• Will Harborne - LinkedIn